Peptide receptor radionuclide therapy of neuroendocrine tumours
Autor: | Dik J. Kwekkeboom, Casper H.J. van Eijck, Tessa Brabander, Gaston J H Franssen, Jaap J.M. Teunissen, Richard A Feelders, Wouter W. de Herder |
---|---|
Přispěvatelé: | Radiology & Nuclear Medicine, Surgery, Internal Medicine |
Rok vydání: | 2016 |
Předmět: |
Oncology
medicine.medical_specialty Pathology Receptors Peptide Peptide receptor Endocrinology Diabetes and Metabolism Disease Octreotide 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine medicine Overall survival Humans Progression-free survival Objective response Radiotherapy business.industry Somatostatin receptor Neuroendocrine Tumors Somatostatin 030220 oncology & carcinogenesis Radionuclide therapy Radiopharmaceuticals business |
Zdroj: | Best Practice & Research Clinical Endocrinology & Metabolism, 30(1), 103-114. Bailliere Tindall Ltd |
ISSN: | 1521-690X |
Popis: | In the past decades, the number of neuroendocrine tumours that are detected is increasing. A relative new and promising therapy for patients with metastasised or inoperable disease is peptide receptor radionuclide therapy (PRRT). This therapy involves an infusion of somatostatin analogues linked to radionuclides like Yttrium-90 or Lutetium-177. Objective response rates are reported in 15-35%. Response rates may vary between type of tumour and radionuclide. Besides the objective response rate, overall survival and progression free survival increase significantly. Also, the quality of life improves as well. Serious side-affects are rare. PRRT is usually well tolerated, also in patients with extensive metastasised disease. Recent studies combined PRRT with other types of therapies. Unfortunately no randomised trials comparing these strategies are available. In the future, more research is needed to evaluate the best therapy combinations or sequence of therapies. (C) 2015 Elsevier Ltd. All rights reserved. |
Databáze: | OpenAIRE |
Externí odkaz: |